Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Artiva Biotherapeutics, Inc. - Common Stock (NQ: ARTV )

6.970 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4
Open 6.970
Bid (Size) 6.500 (10)
Ask (Size) 11.15 (2)
Prev. Close 6.970
Today's Range 6.970 - 6.970
52wk Range 6.910 - 17.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Via Benzinga
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga

Performance

YTD
-30.09%
-30.09%
1 Month
-32.98%
-32.98%
3 Month
-44.55%
-44.55%
6 Month
-41.92%
-41.92%
1 Year
-41.92%
-41.92%

More News

Read More
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Via Talk Markets
Ardent Health Slips After Downsized IPO
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.